---
schema_version: "secwatch.filing_event.v1"
accession: "0001193805-23-001054"
form_type: "8-K"
ticker: "IMUX"
cik: "0001280776"
company_name: "IMMUNIC, INC."
filed_at: "2023-08-03T23:59:59+00:00"
generated_at: "2026-06-12T07:23:23.743910+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Immunic Q2 2023 net loss $24.0M; cash $77.3M funds into Q4 2024

## Summary
- Net loss of $24.0M ($0.54/share) vs $21.9M ($0.72/share) in Q2 2022.
- Cash, cash equivalents and investments at $77.3M as of June 30, 2023.
- R&D expenses $21.2M, up from $16.5M YoY, driven by MS and IMU-856 programs.
- Interim CALLIPER trial data in progressive MS expected fall 2023; ENSURE top-line late 2024.
- Positive Phase 1b IMU-856 data in celiac disease; Phase 2 in active celiac being prepared.

## SEC filing metadata
- accession: 0001193805-23-001054
- form_type: 8-K
- ticker: IMUX
- cik: 0001280776
- company_name: IMMUNIC, INC.
- filed_at: 2023-08-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1280776/000119380523001054/0001193805-23-001054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1280776/000119380523001054/e618816_8k-immunic.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193805-23-001054
- JSON: https://secwatch.observer/filing/0001193805-23-001054.json
- Plain text: https://secwatch.observer/filing/0001193805-23-001054.txt

## Key facts
- Earnings Releases
  IMMUNIC, INC. reported financial results for the quarter ended June 30, 2023.
  - Period: the quarter ended June 30, 2023
  - Result: reported results
  source text: On August 3, 2023, Immunic, Inc. (the "Company") issued a press release announcing its financial results for the quarter ended June 30, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1280776/000119380523001054/0001193805-23-001054-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.